Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1099031 | 0.82 | PAX8 (0.41) | RAB9ALMNAMAPK1HTTALDH1A1 | |
| SCHEMBL27090 | 0.78 | CA2 (0.54) | MAPK1TUBB1ALDH1A1 | |
| SCHEMBL3063279 | 0.77 | KCNQ3 (0.39) | MEN1KMT2A | |
| SCHEMBL7939757 | 0.77 | KDM1A (0.50) | RAB9AMAPK1HTTTUBB1KDM1A | |
| SCHEMBL2811538 | 0.76 | CA2 (0.41) | MAPK1MEN1ALDH1A1KMT2A | |
| SCHEMBL29366053 | 0.76 | LMNA (0.53) | RAB9ALMNAMAPK1HTTTUBB1 | |
| SCHEMBL197204 | 0.76 | LMNA (0.53) | RAB9ALMNAMAPK1HTTTUBB1 | |
| SCHEMBL9464193 | 0.76 | CYP17A1 (0.61) | RAB9ALMNAMAPK1HTTTUBB1 | |
| SCHEMBL11883 | 0.74 | ACHE (0.62) | RAB9ALMNAMAPK1HTTTUBB1 | |
| SCHEMBL352907 | 0.74 | MAPT (0.47) | LMNAMAPK1ALDH1A1SMN1; SMN2PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116640106-A | Phenylpiperazine compound and preparation method and application thereof | 郑州大学 | 2023-08-25 | — | — | CN | claimed |
| US-20230122243-A1 | Heteroaromatic inhibitors of astacin proteinases | VIVORYON THERAPEUTICS N.V. (DE) | 2023-04-20 | — | — | US | claimed |
| CN-114585608-A | Heteroaromatic inhibitors of astacin protease | 维沃永治疗公众有限公司 | 2022-06-03 | — | — | CN | claimed |
| EP-3986868-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | Vivoryon Therapeutics N.V. (DE) | 2022-04-27 | — | — | EP | claimed |
| EP-3692101-B1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTR S R L (IT) | 2022-01-12 | — | — | EP | claimed |
| CN-113121517-A | Triazole derivative and preparation method and application thereof | 中山大学 | 2021-07-16 | — | — | CN | claimed |
| WO-2020249760-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | VIVORYON THERAPEUTICS AG (DE) | 2020-12-17 | — | — | WO | claimed |
| EP-3750878-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | Vivoryon Therapeutics AG (DE) | 2020-12-16 | — | — | EP | claimed |
| EP-3692101-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | Alfa Instruments S.r.l. (IT) | 2020-08-12 | — | — | EP | claimed |
| EP-3122751-B1 | CONDENSED [1,4]DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | claimed |
| US-20060270653-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-11-30 | — | — | US | claimed |
| WO-2006058303-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | claimed |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | claimed |
| US-6723743-B1 | TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| US-5916920-A | CONTROLLING NEUROTRANSMITTER RECPETORS; NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS | ELI LILLY AND COMPANY (US) | 1999-06-29 | — | — | US | claimed |
| CN-1202103-A | Excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 1998-12-16 | — | — | CN | claimed |
| EP-0774455-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1997-05-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122243-A1 | Heteroaromatic inhibitors of astacin proteinases | BMP1, DPEP1, MEP1A | RAB9A 3956/4885LMNA 2719/4885MAPK1 2567/4885 |
| US-20060270653-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | RAB9A 1944/4885LMNA 4093/4885MAPK1 2911/4885 |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | DPP8, DPP4, DPP7 | RAB9A 2916/4885LMNA 1878/4885MAPK1 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.